A Newfoundland and Labrador health tech company, JVPLabs, is set to receive provincial funding to bring its innovative congestive heart failure monitoring solution to market. The government has announced an investment of over $500,000 to support the research and development of the JVPClinic medical device.
JVPLabs is developing non-invasive technology to enhance the assessment of congestive heart failure patients by measuring jugular venous pressure height in both hospital and home settings. The JVPClinic device uses advanced algorithms and artificial intelligence to analyze subtle motion signatures from neck images, providing valuable insights into heart function.
This technology enables doctors to adjust medications before patients develop severe symptoms, such as shortness of breath, with the goal of reducing hospital congestion and keeping patients comfortable at home. Congestive heart failure is a widespread and costly condition, affecting over 25 million people worldwide, including approximately 750,000 Canadians, with 100,000 new diagnoses annually.
The provincial government’s funding will support the development and fabrication of JVPClinic devices, research and development, third-party testing, and AI development. JVPLabs has successfully completed several R&D projects with the department, leading to earlier prototypes of the JVPClinic device used in clinical trials at Eastern Health.
About Congestive Heart Failure
Congestive heart failure is one of the most common and costly diseases worldwide, reaching epidemic levels and expanding rapidly. The condition affects millions globally, with significant implications for healthcare systems.
The JVPClinic Technology
The JVPClinic device captures images of the neck and uses powerful algorithms and artificial intelligence to extract subtle motion signatures. This information provides details regarding heart function, enabling healthcare professionals to make informed decisions about patient care.
The provincial government’s investment in JVPLabs demonstrates its commitment to supporting innovative healthcare solutions in the region. With this funding, JVPLabs is poised to make a significant impact in the management of congestive heart failure.
